A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer

The study is to explore the the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in combination with Serplulimab (anti-PD-1 humanized monoclonal antibody injection) in patients with advanced lung cancer.

Trial Details

NCT ID
NCT07253142
Phase
PHASE2
Sponsor
Shanghai Henlius Biotech
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • HLX43 dose 1
  • HLX43 dose 2
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Fu'zhou, Fujian, China
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Nanning, Guangxi, China|22.81667,108.31667
  • Cangzhou, Hebei, China|38.31124,116.85334

Key Eligibility Criteria

  • 1\. Voluntarily to participate in the trial, and be able to complete the study as required by the protocol;
  • 2\. Age ≥18 years and ≤75 years;
  • 3\. Histologically or cytologically confirmed locally advanced (stage IIIB/IIIC) or metastatic (stage IV) NSCLC unsuitable for radical treatment wi…
  • 4\. Subjects must meet the following prior treatment requirements:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →